Profound mishandling of protein glycation degradation products in uremia and dialysis

被引:120
作者
Agalou, S
Ahmed, N
Babaei-Jadidi, R
Dawnay, A
Thornalley, PJ
机构
[1] Univ Essex, Dept Sci Biol, Colchester CO4 3SQ, Essex, England
[2] St Bartholomews & Royal London Sch Med & Dent, Renal Res Labs, St Bartholomews Hosp, London, England
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2005年 / 16卷 / 05期
基金
英国惠康基金;
关键词
D O I
10.1681/ASN.2004080635
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The aim of this study was to define the severe deficits of protein glycation adduct clearance in chronic renal failure and elimination in peritoneal dialysis (PD) and hemodialysis (HD) therapy using a liquid chromatography-triple quadrupole mass spectrometric detection method. Physiologic proteolysis of proteins damaged by glycation, oxidation, and nitration forms protein glycation, oxidation, and nitration free adducts that are released into plasma for urinary excretion. Inefficient elimination of these free adducts in uremia may lead to their accumulation. Patients with mild uremic chronic renal failure had plasma glycation free adduct concentrations increased up to five-fold associated with a decline in renal clearance. In patients with ESRD, plasma glycation free adducts were increased up to 18-fold on PD and up to 40-fold on HD. Glycation free adduct concentrations in peritoneal dialysate increased over 2- to 12-h dwell time, exceeding the plasma levels markedly. Plasma glycation free adducts equilibrated rapidly with dialysate of HD patients, with both plasma and dialysate concentrations decreasing during a 4-h dialysis session. It is concluded that there are severe deficits of protein glycation free adduct clearance in chronic renal failure and in ESRD on PD and HD therapy.
引用
收藏
页码:1471 / 1485
页数:15
相关论文
共 37 条
[1]   Estimation of α-oxoaldehydes formed from the degradation of glycolytic intermediates and glucose fragmentation in blood plasma of human subjects with uraemia [J].
Agalou, S ;
Karachalias, N ;
Thornalley, PJ ;
Tucker, B ;
Dawnay, AB .
MAILLARD REACTION IN FOOD CHEMISTRY AND MEDICAL SCIENCE: UPDATE FOR THE POSTGENOMIC ERA, 2002, 1245 :181-182
[2]  
Ahmed N, 2002, BIOCHEM J, V364, P1
[3]  
[Anonymous], 1999, Clin. Lab
[4]   Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients [J].
Cheung, AK ;
Sarnak, MJ ;
Yan, GF ;
Dwyer, JT ;
Heyka, RJ ;
Rocco, MV ;
Teehan, BP ;
Levey, AS .
KIDNEY INTERNATIONAL, 2000, 58 (01) :353-362
[5]  
de la Motte S, 2002, INT J CLIN PHARM TH, V40, P60
[6]  
Degenhardt TP, 1998, CELL MOL BIOL, V44, P1139
[7]   Characterization of uremic toxin transport by organic anion transporters in the kidney [J].
Deguchi, T ;
Kusuhara, H ;
Takadate, A ;
Endou, H ;
Otagiri, M ;
Sugiyama, Y .
KIDNEY INTERNATIONAL, 2004, 65 (01) :162-174
[8]   Metabolic transit and in vivo effects of melanoidins and precursor compounds deriving from the Maillard reaction [J].
Faist, V ;
Erbersdobler, HF .
ANNALS OF NUTRITION AND METABOLISM, 2001, 45 (01) :1-12
[9]   Early and advanced glycosylation end products - Kinetics of formation and clearance in peritoneal dialysis [J].
Friedlander, MA ;
Wu, YC ;
Elgawish, A ;
Monnier, VM .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (03) :728-735
[10]  
Fujisawa M, 2000, J AM SOC NEPHROL, V11, P1889, DOI 10.1681/ASN.V11101889